<DOC>
	<DOCNO>NCT00013585</DOCNO>
	<brief_summary>A decrease mental function often occur patient HIV . Antiretroviral ( ARV ) drug use treat entirely effective . Some therapy could play role . The drug selegiline pill form use treat Parkinson 's disease , serious brain disorder . It believe drug might protect brain repair damage . This study use drug `` patch '' form , approve Food Drug Administration ( FDA ) , see help decrease mental function patient HIV . The purpose study evaluate use selegiline transdermal system ( STS ) treatment decrease mental function patient HIV .</brief_summary>
	<brief_title>Safety Effectiveness Selegiline `` Patch '' Decreased Mental Function HIV Patients</brief_title>
	<detailed_description>Cognitive impairment common adverse effect HIV infection progress dementia . ARVs current therapy , treatment response frequently unsatisfactory , short live , agent poorly tolerate dos adequate central nervous system ( CNS ) penetration . An adjunctive therapy interferes cascade event trigger virus likely play important role . Oral selegiline approve marketed drug symptomatic treatment Parkinson 's disease . Studies suggest selegiline neuroprotective effect may exert `` rescue effect '' die injured neuron . This study propose use transdermal selegiline , may deliver great dose level oral administration , treatment HIV-associated cognitive impairment . This two-step study , step last 24 week . Step 1 double-blind Step 2 open label . At entry , patient randomly assign receive either STS placebo . One STS patch apply daily time 24 week . Patients evaluate clinic entry Weeks 2 , 4 , 8 , 12 , 16 , 24 . Cognitive status evaluate performance series neuropsychological assessment . Patients complete Step 1 may participate Step 2 . Patients placebo Step 1 receive active STS treatment Step 2 . The STS patch apply daily additional 24 week patient evaluate clinic Weeks 28 , 36 , 48 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Selegiline</mesh_term>
	<criteria>Note : This trial close accrual 12/15/04 . Use lowerdose STS discontinue 05/31/05 . Any patient join study 05/31/05 assign interventional arm currently enrol Step 2 receive higherdose STS . HIV infect Stable antiHIV therapy antiHIV therapy least 8 week prior study screen AIDS Dementia Complex Stage great 0 Decreased mental function show test screen IQ 70 great Willing use acceptable method contraception study 3 month follow study Tumor involve large organ require chemotherapy . Patients basal cell carcinoma , situ carcinoma cervix , Kaposi 's sarcoma exclude . Serious mental illness , opinion investigator , might interfere study Reserpine meperidine within 7 day prior study entry Nefazodone within 14 day prior study entry Monoamine oxidase inhibitor , include selegiline , within 30 day prior study entry Sympathomimetic medication , include counter diet cold ( oral nasal ) remedy , within 14 day study entry Decreased blood pressure stand Uncontrolled high blood pressure Active symptomatic AIDSdefining opportunistic infection within 30 day prior study entry Nervous system disorder multiple sclerosis , stroke , serious head injury , uncontrolled epilepsy , Tourette 's syndrome , Huntington 's disease , dementia due alcohol abuse , vitamin B12 deficiency , syphilis CNS infection neoplasms include cytomegalovirus ( CMV ) encephalitis , toxoplasmosis , primary metastatic CNS lymphoma , progressive multifocal leukoencephalopathy , cryptococcal fungal meningitis , tuberculous CNS infection , untreated neurosyphilis Any condition , investigator 's opinion , would interfere study Certain investigational drug within 30 day study entry Allergic selegiline STS patch Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Cognitive Disorders</keyword>
	<keyword>AIDS Dementia Complex</keyword>
	<keyword>Selegiline</keyword>
	<keyword>Administration , Cutaneous</keyword>
	<keyword>Neuroprotective Agents</keyword>
</DOC>